Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel ...
A systematic review of 75 studies from 2021 to 2025 maps trends in specialized medical language models for diagnosis and the ...
Psychiatric drug development still leans on rating scales developed decades ago: subjective instruments that capture how a patient describes feeling but not what the brain is doing. In major ...
Timothy A. Yap, MBBS, Ph.D., FRCP, of The University of Texas MD Anderson Cancer Center to present results from the dose escalation phase of the ACR-2316 Phase 1/2 trial on November 20, 2026 ...
An openEHR-based repository at Charité has been reused across five studies covering about 16,000 patients, with 57 of its 125 ...
The “Performa” Observatory at LIUC Business School analyses and compares experiences, generating evidence to inform ...
Treatment-emergent skin toxic effects during first-line enfortumab vedotin plus pembrolizumab were associated with longer ...
Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the ...
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced ...
Interview: Rakesh Bhardwaj discusses Lupin’s AI priorities, its data foundations and why CIOs must help redesign work, the ...
Chief Nursing Officers (CNOs) at large U.S. hospitals are confident in their nursing teams, but not in the tools those teams use ...
Dr. Bender brings a proven track record in therapeutic development, company evolution, and strategic execution to help guide Diagonal’s continued pipeline progress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results